You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
PACAP38 and PAC1 receptor blockade: a new target for headache?
|
|---|---|
| Published in |
The Journal of Headache and Pain, August 2018
|
| DOI | 10.1186/s10194-018-0893-8 |
| Pubmed ID | |
| Authors |
Eloisa Rubio-Beltrán, Edvige Correnti, Marie Deen, Katharina Kamm, Tim Kelderman, Laura Papetti, Simone Vigneri, Antoinette MaassenVanDenBrink, Lars Edvinsson, On behalf of the European Headache Federation School of Advanced Studies (EHF-SAS) |
| Abstract |
Pituitary adenylate cyclase activating polypeptide-38 (PACAP38) is a widely distributed neuropeptide involved in neuroprotection, neurodevelopment, nociception and inflammation. Moreover, PACAP38 is a potent inducer of migraine-like attacks, but the mechanism behind this has not been fully elucidated.Migraine is a neurovascular disorder, recognized as the second most disabling disease. Nevertheless, the antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor are the only prophylactic treatment developed specifically for migraine. These antibodies have displayed positive results in clinical trials, but are not effective for all patients; therefore, new pharmacological targets need to be identified.Due to the ability of PACAP38 to induce migraine-like attacks, its location in structures previously associated with migraine pathophysiology and the 100-fold selectivity for the PAC1 receptor when compared to VIP, new attention has been drawn to this pathway and its potential role as a novel target for migraine treatment. In accordance with this, antibodies against PACAP38 (ALD 1910) and PAC1 receptor (AMG 301) are being developed, with AMG 301 already in Phase II clinical trials. No results have been published so far, but in preclinical studies, AMG 301 has shown responses comparable to those observed with triptans. If these antibodies prove to be effective for the treatment of migraine, several considerations should be addressed, for instance, the potential side effects of long-term blockade of the PACAP (receptor) pathway. Moreover, it is important to investigate whether these antibodies will indeed represent a therapeutic advantage for the patients that do not respond the CGRP (receptor)-antibodies.In conclusion, the data presented in this review indicate that PACAP38 and PAC1 receptor blockade are promising antimigraine therapies, but results from clinical trials are needed in order to confirm their efficacy and side effect profile. |
X Demographics
The data shown below were collected from the profiles of 16 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 5 | 31% |
| Denmark | 2 | 13% |
| United States | 1 | 6% |
| Italy | 1 | 6% |
| New Zealand | 1 | 6% |
| Unknown | 6 | 38% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 12 | 75% |
| Science communicators (journalists, bloggers, editors) | 2 | 13% |
| Scientists | 2 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 61 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 8 | 13% |
| Student > Ph. D. Student | 8 | 13% |
| Other | 7 | 11% |
| Researcher | 6 | 10% |
| Student > Bachelor | 3 | 5% |
| Other | 5 | 8% |
| Unknown | 24 | 39% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 25% |
| Biochemistry, Genetics and Molecular Biology | 6 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 8% |
| Neuroscience | 5 | 8% |
| Nursing and Health Professions | 2 | 3% |
| Other | 3 | 5% |
| Unknown | 25 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 26. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 March 2024.
All research outputs
#1,437,527
of 24,916,485 outputs
Outputs from The Journal of Headache and Pain
#165
of 1,503 outputs
Outputs of similar age
#29,855
of 336,210 outputs
Outputs of similar age from The Journal of Headache and Pain
#11
of 44 outputs
Altmetric has tracked 24,916,485 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,503 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 19.0. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 336,210 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 44 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.